Evommune

Evommune PEG

The PEG Ratio (Price/Earnings-to-Growth) of Evommune (EVMN) as of Oct 28, 2026 is -1.34.

PEG

-1.34

Last updated:

PEG Ratio (Price/Earnings-to-Growth) of Evommune is 2025 -1.34 . PEG Ratio (Price/Earnings-to-Growth) of Evommune was 2024 - . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Evommune Stock analysis

What does Evommune do? Evommune Inc generates revenue through its research and development activities focused on inflammatory diseases. The company employs a tissue-based approach using skin as a lens to develop transformative medicines in immunology and dermatology. Its primary products are advanced therapeutic solutions for inflammatory conditions, targeting pharmaceutical companies seeking to accelerate drug development. The firm serves the biotechnology and pharmaceutical sectors with its innovative R&D services. The company's business model centers on providing specialized research services to accelerate medicine development. Evommune, Inc. leverages skin tissue insights to uncover new approaches for immunology and dermatology treatments. Its services are purchased by pharmaceutical firms aiming to enhance their drug development pipelines. The firm's R&D focus on inflammatory diseases positions it as a key partner for companies in the biotech industry. Evommune Inc's revenue streams come from contractual R&D services for pharmaceutical clients. The company's tissue-based methodology for inflammatory disease research is its core offering. It develops and delivers research insights that help clients advance their medicine development in immunology and dermatology. The firm's approach targets the biotechnology sector's need for faster, more effective drug development solutions. Evommune is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Evommune stock

PEG Ratio (Price/Earnings-to-Growth) of Evommune is -1.34 in 2025.

On Eulerpool you can find the complete historical development of PEG Ratio (Price/Earnings-to-Growth) Evommune since 2006 – with annual values, charts, and detailed analysis.

The PEG ratio adjusts the P/E ratio by the expected earnings growth rate. A PEG below 1 may indicate an undervalued stock relative to its growth potential.

PEG = P/E Ratio / Expected Annual EPS Growth Rate

To evaluate PEG Ratio (Price/Earnings-to-Growth)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for PEG Ratio (Price/Earnings-to-Growth).

A 'good' varies by industry and company stage. On Eulerpool, you can compare PEG Ratio (Price/Earnings-to-Growth)'s Evommune with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Evommune

All Key Metrics — Evommune